Effects of smoking cessation and nicotine substitution on systemic eicosanoid production in man.
This study investigated the effects of smoking cessation with and without nicotine substitution on the excretion of major urinary metabolites of thromboxane A2 and prostacyclin, 11-dehydrothromboxane B2 and 2,3-dinor-6-ketoprostaglandin F1alpha, respectively, as well as on the excretion of leukotriene E4 in man. Urine samples were obtained from 20 healthy non-smoking controls and from 60 healthy smoking volunteers before, and 3, 7 and 14 days after smoking cessation. Fifteen smokers quit smoking without nicotine substitution, 15 used nicotine chewing gum and 30 used nicotine patches as a substitution therapy. Urinary thiocyanate as well as cotinine and trans-3'-hydroxycotinine excretions were used as compliance and nicotine substitution indicators. 11-Dehydrothromboxane B2, 2,3-dinor-6-ketoprostaglandin F1alpha and leukotriene E4 excretion was about two, three and five times higher in smokers than in controls, respectively. Three days after smoking cessation without nicotine substitution, 11-dehydrothromboxane B2 and 2,3-dinor-6-ketoprostaglandin F1alpha levels were lowered to 75% (P<0.01) and 80% (P<0.05) of the initial values, and after 14 days to 50% (P<0.01) and 60% (P<0.05), respectively. In 3 days leukotriene E4 excretion was dropped to 70% of the initial value (P<0.05), but no further decrease was observed during the study. In individuals using nicotine chewing gum or nicotine patches no significant changes were observed in the analytes during the 2-week follow-up. The increased systemic eicosanoid synthesis observed in smokers may be involved in the harmful cardiovascular effects of smoking. The fact that eicosanoid production remains at pre-cessation level in volunteers who quit smoking but use nicotine substitution may be involved in the risk of cardiovascular complications reported during nicotine replacement therapy.
Saareks
V
V
Department of Pharmacological Sciences, University of Tampere, Finland. virpi.saareks@uta.fi
Ylitalo
P
P
Alanko
J
J
Mucha
I
I
Riutta
A
A
D000279:Administration, Cutaneous; D000328:Adult; D000704:Analysis of Variance; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D015777:Eicosanoids / Q000096:biosynthesis* / Q000652:urine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000031:analogs & derivatives / Q000494:pharmacology*; D018722:Nicotinic Agonists / Q000494:pharmacology*; D011109:Polymethacrylic Acids / Q000494:pharmacology*; D011145:Polyvinyls / Q000494:pharmacology*; D016540:Smoking Cessation; D061485:Tobacco Use Cessation Devices
D000697:Central Nervous System Stimulants; D015777:Eicosanoids; D018722:Nicotinic Agonists; D011109:Polymethacrylic Acids; D011145:Polyvinyls; D009538:Nicotine